GBI has unveiled SOURCE, a comprehensive market tool for tracking the Chinese biotechnology and pharmaceutical sectors – the first of its kind in China. SOURCE covers the breadth of the Chinese biopharma industry, providing users with a unique view into the competitive landscape and ever-evolving regulatory climate, while simultaneously arming subscribers with an unmatched well of…
GBI has launched its first information content product, the China Pharmaceutical and Biotechnology Review (CPB Review). The CPB Review provides in-depth analysis and timely coverage of China’s pharmaceutical and biotechnology sectors, highlighting burgeoning trends and developments through exclusive, original articles and interviews with industry leaders. The CPB Review distinguishes itself from other China healthcare periodicals…
